Excreted Unchanged %
Hepatic
Half-Life (Normalesrd) Hours
2-4/No data
Plasma Protein Binding %
80
Volume Of Distribution L/Kg
9-11
Dose For Normal Renal Function
2 mg q3-4h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
75% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: No data
Supplement For Dialysis [Recommendation Level]: Pd
PD: No data
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, titrate, [D]
References
Gillis JC, Benfield P, Goa KL. Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs. 1995; 50: 157-75. [PMID: 7588085] / Ramsey R, Higbee M, Maesner J, et al. Influence of age on the pharmacokinetics of butorphanol. Pharmacol Toxicol. 1987; 60(Suppl 2): 8-16. [PMID unavailable]